Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30324926 | 0.89 | L3MBTL1 (0.45) | L3MBTL1OPRM1OPRL1HTR2CSLC6A4 | |
| SCHEMBL29502278 | 0.88 | L3MBTL1 (0.47) | L3MBTL1HTR2CSLC6A4TMEM97SIGMAR1 | |
| SCHEMBL29751192 | 0.85 | L3MBTL1 (0.42) | L3MBTL1HTR2CSLC6A4ABCB1TMEM97 | |
| SCHEMBL21996926 | 0.81 | SMN1; SMN2 (0.49) | L3MBTL1BCHETMEM97SIGMAR1 | |
| SCHEMBL21997469 | 0.81 | L3MBTL1 (0.47) | L3MBTL1ABCB1TMEM97SIGMAR1 | |
| SCHEMBL25726330 | 0.81 | L3MBTL1 (0.47) | L3MBTL1ABCB1TMEM97SIGMAR1 | |
| SCHEMBL29502387 | 0.81 | L3MBTL1 (0.47) | L3MBTL1HTR2CSLC6A4PDK2AGTR2 | |
| SCHEMBL13567987 | 0.80 | L3MBTL1 (0.43) | L3MBTL1OPRM1OPRL1HTR2CSLC6A4 | |
| SCHEMBL13567992 | 0.80 | L3MBTL1 (0.43) | L3MBTL1OPRM1OPRL1HTR2CSLC6A4 | |
| SCHEMBL26351569 | 0.79 | SIGMAR1 (0.42) | L3MBTL1HTR2CTMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | L3MBTL1 1897/4885OPRM1 4467/4885OPRL1 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.